<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 3 -->
<!-- Creation date: 2014-08-11T20:21:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:insv="http://insitevision.com/20140630" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="insv-20140630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20110526_0_705999x716283" unitRef="Patent" decimals="INF" id="id_3815551_872F2087-FA20-4012-9D05-688E25FDDF8B_2_0">3</insv:NumberOfPatentsInfringed>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20110526_0_711809x726294" unitRef="Patent" decimals="INF" id="id_3815551_872F2087-FA20-4012-9D05-688E25FDDF8B_1_0">1</insv:NumberOfPatentsInfringed>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x713713" unitRef="shares" decimals="INF" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_3001_2">14791376</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x713713" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_3001_1">0.60</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x715581" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_4001_3">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4AA0F5F3-C8D8-49D0-8D91-8F8F83A29386_1001_0">6400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_0_20140811_0" unitRef="shares" decimals="INF" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_2_500005">131951033</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5378----1410-Q0004_STD_0_20080229_0" unitRef="pure" decimals="INF" id="id_3815551_6E705585-7E6D-4C7E-ABAD-2BAEF9AD5B84_1001_2">0.16</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5378----1410-Q0004_STD_0_20080229_0" unitRef="iso4217_USD" decimals="-5" id="id_3815551_6E705585-7E6D-4C7E-ABAD-2BAEF9AD5B84_1001_0">60000000</us-gaap:DebtInstrumentFaceAmount>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20110430_0" unitRef="Patent" decimals="INF" id="id_3815551_3F878C4E-7D0C-4C52-B1B2-D1C043551C43_1_0">5</insv:NumberOfPatentsInfringed>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20110430_0_705999x716283" unitRef="Patent" decimals="INF" id="id_3815551_3F878C4E-7D0C-4C52-B1B2-D1C043551C43_2_0">4</insv:NumberOfPatentsInfringed>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20110430_0_711809x726294" unitRef="Patent" decimals="INF" id="id_3815551_3F878C4E-7D0C-4C52-B1B2-D1C043551C43_3_0">1</insv:NumberOfPatentsInfringed>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20130531_0_705999x716283" unitRef="Patent" decimals="INF" id="id_3815551_9C72B984-78CB-4023-AF3D-17E0CC9800C2_1_0">3</insv:NumberOfPatentsInfringed>
  <insv:NumberOfPatentsInfringed contextRef="eol_PE5378----1410-Q0004_STD_0_20130531_0_711809x726294" unitRef="Patent" decimals="INF" id="id_3815551_9C72B984-78CB-4023-AF3D-17E0CC9800C2_2_0">1</insv:NumberOfPatentsInfringed>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5378----1410-Q0004_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1002_29">6610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_34">131951033</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_30">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_3001_9">12894583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_3001_7">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_3001_7">19657911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_9AE9E9DB-1DC8-43DF-844D-8D504217A9F0_1001_0">4600447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_27">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_29">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_3001_9">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_33">240000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_32">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_28">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_3001_8">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_3001_8">19016204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_35">131951033</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_24" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_20">5032000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_17">791000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_15">1408000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_36">166011000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_13">542000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_38">-2222000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedRoyaltiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_16">871000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_37">-169553000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_21">1000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_26" />
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_14">1420000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_22">1003000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_23">7035000</us-gaap:Liabilities>
  <us-gaap:IncentiveFromLessor contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1001_34">201000</us-gaap:IncentiveFromLessor>
  <us-gaap:CommonStockValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_31">1320000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_39">4813000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_5">107000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_4">301000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_3815551_D55610C5-2DA4-47DB-A11F-99C10D4F056A_2_0">1200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_9">1749000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_10">4813000</us-gaap:Assets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_1866947F-02F8-491C-A334-0211878D150C_1001_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_2">2475000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_1866947F-02F8-491C-A334-0211878D150C_1001_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_6">181000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_1_8">3064000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0_708293x857455_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-5" id="id_3815551_05A0A3E8-1D4D-42BB-A3EC-A48531917F0E_1001_0">1900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x713713" unitRef="shares" decimals="INF" id="id_3815551_FA816831-831D-46A1-8744-B3ABC6667510_2001_2">14791376</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x715581" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_3815551_FA816831-831D-46A1-8744-B3ABC6667510_3001_3">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4AA0F5F3-C8D8-49D0-8D91-8F8F83A29386_1003_0">791000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <insv:ClassOfWarrantOrRightPotentialProceedsIfExercisedForCash contextRef="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x715581" unitRef="iso4217_USD" decimals="0" id="id_3815551_FA816831-831D-46A1-8744-B3ABC6667510_3001_5">11093532</insv:ClassOfWarrantOrRightPotentialProceedsIfExercisedForCash>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5378----1410-Q0004_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2001_28">1323000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_34">131951033</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_30">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_1001_2">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_1001_2">17097984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_27">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_29">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_33">240000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_32">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_28">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_35">131951033</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_18">826000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_24" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_20">48390000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_17">1685000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_15">1090000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_36">165549000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_13">394000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_38">-35154000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedRoyaltiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_16">776000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:SecuredDebtCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_19">41281000</us-gaap:SecuredDebtCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_37">-202023000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_21">7000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_26" />
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_14">2338000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_22">922000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_23">49319000</us-gaap:Liabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_31">1320000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_39">14165000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_5">1114000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_4">1026000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_9">1431000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_10">14165000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_2">3251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_3">5000000</us-gaap:ShortTermInvestments>
  <us-gaap:DeferredFinanceCostsCurrentNet contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_7">2248000</us-gaap:DeferredFinanceCostsCurrentNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_6">95000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_8">12734000</us-gaap:AssetsCurrent>
  <insv:IncreaseInCommonStockReservedForIssuance contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3815551_A5D0F684-7AC8-40CA-9F0A-8228514A00A2_2_2">2639020</insv:IncreaseInCommonStockReservedForIssuance>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5378----1410-Q0004_STD_0_20131231_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4AA0F5F3-C8D8-49D0-8D91-8F8F83A29386_1002_0">1685000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <insv:DebtInstrumentMaturityYear contextRef="eol_PE5378----1410-Q0004_STD_1_20080229_0" id="id_3815551_6E705585-7E6D-4C7E-ABAD-2BAEF9AD5B84_1_1">2019</insv:DebtInstrumentMaturityYear>
  <us-gaap:LegalFees contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_711502x716112_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_D86BF097-085A-4BF9-9224-811F873D8C30_1001_1">100000</us-gaap:LegalFees>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_711809x1077185" unitRef="iso4217_USD" decimals="-5" id="id_3815551_20CBCF58-99CE-4886-BB8D-B7F5EDC51C53_1001_0">6000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_711809x1077186" unitRef="iso4217_USD" decimals="-5" id="id_3815551_20CBCF58-99CE-4886-BB8D-B7F5EDC51C53_2001_2">6000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_2001_0">6000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_2001_1">41300000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:DebtIssuanceCosts contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_D86BF097-085A-4BF9-9224-811F873D8C30_2001_0">2100000</us-gaap:DebtIssuanceCosts>
  <insv:ExtinguishmentOfDebtInterestAmount contextRef="eol_PE5378----1410-Q0004_STD_1_20140610_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_2001_2">2800000</insv:ExtinguishmentOfDebtInterestAmount>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_17">0.08</us-gaap:EarningsPerShareBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_3_0">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_18">0.08</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_21">132505000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_3_3">0.902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_6C3362BF-5115-4278-A06A-AF1434ABB033_4_5">554000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_19">10364000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_3_1">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_9AE9E9DB-1DC8-43DF-844D-8D504217A9F0_2_1">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_3_2">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_3815551_9AE9E9DB-1DC8-43DF-844D-8D504217A9F0_2_2">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_3815551_917F0F1A-2C37-4E28-A372-A19F8905857B_4_0">30706276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_3815551_4FBFBC85-0FEB-4272-AF30-695DC54394C6_2_0">3356847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_20">131951000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_21">30000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_22">1000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_33">1000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="INF" id="id_3815551_4FBFBC85-0FEB-4272-AF30-695DC54394C6_2_1">749000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_14">28000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_25">5046000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:InterestPaid contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_32">4056000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_10">-500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_5">24500000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_12">18000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ContractsRevenue contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_3">14490000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_11">14327000</us-gaap:OperatingIncomeLoss>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_2">10010000</us-gaap:RoyaltyRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_15">10195000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_16">-166000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_26">-5046000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_15">-316000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_8">3077000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_7">478000</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromInterestReceived contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_31">3000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:CostOfServicesLicensesAndServices contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_9">252000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_27">5287000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_23">-31000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_17">-101000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_14">-959000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_13">519000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_3">52000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_2_4">208000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_4_2">478000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_7">6844000</us-gaap:ResearchAndDevelopmentExpense>
  <insv:StockBasedCompensationNotExpectedToVest contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_3815551_7A841DB2-E532-4E13-BF2A-EC27D7A386D7_2_1">332000</insv:StockBasedCompensationNotExpectedToVest>
  <insv:InterestExpenseAndOtherNet contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_13">4160000</insv:InterestExpenseAndOtherNet>
  <insv:CostOfSalesAndServicesIncludingOperatingExpenses contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_4_10">10173000</insv:CostOfSalesAndServicesIncludingOperatingExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_1004_1">311000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_2004_0">167000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0_715329x708980" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_1004_0">476000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20130630_0_715329x739390" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_2004_1">2000</us-gaap:AllocatedShareBasedCompensationExpense>
  <dei:TradingSymbol contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_1_400000">INSV</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_1_400001">INSITE VISION INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D4E441FD-2EF5-4B9B-8F61-40AFAEAF71C1_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_1_400004">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D4E441FD-2EF5-4B9B-8F61-40AFAEAF71C1_1_3">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D4E441FD-2EF5-4B9B-8F61-40AFAEAF71C1_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D4E441FD-2EF5-4B9B-8F61-40AFAEAF71C1_1_2">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_1_400002">0000802724</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_73F482D0-5468-443D-9010-F737F6467496_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D4E441FD-2EF5-4B9B-8F61-40AFAEAF71C1_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_5001_5">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_17">0.25</us-gaap:EarningsPerShareBasic>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_BDA8DB6C-BF72-4352-9FB4-2EA5504B980B_2001_2">P7Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_2_0">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_5001_6">0.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_18">0.25</us-gaap:EarningsPerShareDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_5001_6">146129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_21">132333000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_6D6485EB-6339-4CC3-B3F3-F3484D9F387B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following is a summary of stock option activity for the
 indicated periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number of&lt;br /&gt;
 shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;br /&gt;
 Remaining&amp;#xA0;Contractual&lt;br /&gt;
 Term (Years)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;br /&gt;
 (in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,097,984&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,777,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(70,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(146,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,657,911&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested and expected to vest at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,016,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,894,583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_38B86939-F101-468B-88D9-282288BEAB24_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The following table shows outstanding warrants as of June&amp;#xA0;30,
 2014, all of which were issued in the July 2011 private placement
 financing transaction. All of the outstanding warrants have
 cashless exercise provisions in the event the registration
 statement registering the resale of the shares of common stock
 issuable upon exercise of the warrants is not effective or the
 prospectus forming a part of the registration statement is not
 current. All warrants are exercisable for common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 37.5pt"&gt;
 Date Issued&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Warrant&amp;#xA0;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Expiration&amp;#xA0;Date&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Potential&amp;#xA0;Proceeds&amp;#xA0;if&lt;br /&gt;
 Exercised for Cash&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 July&amp;#xA0;18, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,791,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;July&amp;#xA0;18,&amp;#xA0;2016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,093,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_2_3">0.882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_3815551_6C3362BF-5115-4278-A06A-AF1434ABB033_3_5">382000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_5001_3">0.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_19">506000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_50964978-4E19-4190-BFBB-43CEA2208DDF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table provides a summary of changes in the fair value
 of the Company&amp;#x2019;s Level 3 financial liabilities for the six
 months ended June&amp;#xA0;30, 2014 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#xA0;1,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net decrease in fair value of warrant liability on
 remeasurement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;791&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_172DE02D-40CB-49C2-AA44-C652BDB9E508_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The effect of recording stock-based compensation for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation expense by type of award:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Employee stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Scientific Advisory Board stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_DED8F85A-C392-484D-BEC6-81D777D25ECF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Note 1. Significant Accounting Policies and Use of
 Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The accompanying unaudited condensed consolidated financial
 statements include the accounts of InSite Vision Incorporated
 (&amp;#x201C;InSite&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) and its
 wholly-owned subsidiaries. All significant intercompany accounts
 and transactions have been eliminated in the preparation of the
 condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The accompanying unaudited condensed consolidated financial
 statements have been prepared in accordance with accounting
 principles generally accepted in the United States (&amp;#x201C;U.S.
 GAAP&amp;#x201D;) for interim financial information. Accordingly, they
 do not include all of the information and footnotes required for
 complete financial statements. In the opinion of management, all
 adjustments, consisting of normal recurring adjustments, considered
 necessary for a fair presentation of the Company&amp;#x2019;s financial
 results and financial condition have been included. Operating
 results for the three and six months ended June&amp;#xA0;30, 2014 are
 not necessarily indicative of the results that may be expected for
 any future period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Company operates in one segment using one measure of
 profitability to manage its business.&amp;#xA0;All of the
 Company&amp;#x2019;s long-lived assets are located in the United States.
 Revenues are primarily royalties from the North American license
 (the &amp;#x201C;Akorn License&amp;#x201D;) of AzaSite to Akorn, Inc.
 (&amp;#x201C;Akorn&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On June&amp;#xA0;10, 2014, the Company entered into the Third Amendment
 to License Agreement (the &amp;#x201C;Amendment&amp;#x201D;) with Akorn to
 amend the Akorn License. Under the Amendment, Akorn paid the
 Company an amendment fee of $6.0 million in return for a lower
 royalty on net sales of AzaSite in North America. The $6.0 million
 was used by the Company to repurchase and cancel the AzaSite Notes
 (for further discussion, see Note 5). Effective April&amp;#xA0;1, 2014,
 for annual net sales of AzaSite, the royalty is (1)&amp;#xA0;8.0% on
 net sales less than $20.0 million, subject to increase to 9.0% in
 the event that Akorn enters into certain settlements with third
 parties seeking to launch generic versions of AzaSite,
 (2)&amp;#xA0;12.5% on net sales greater than or equal to $20.0 million
 and less than or equal to $50.0 million and (3)&amp;#xA0;15.0% on net
 sales in excess of $50.0 million. For annual net sales of AzaSite
 Xtra, the royalty would be 12.5% on net sales less than $30.0
 million and 15.0% on net sales greater than or equal to $30.0
 million. The Company waived any right to consent to any settlements
 regarding AzaSite (for further discussion, see Note 7) and agreed
 to cooperate to effectuate any such settlement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Amendment further provides that in the event AzaSite Xtra has
 received regulatory approval and has been commercially launched by
 Akorn, as to any calendar quarter, Akorn would not be obligated to
 pay any royalties as to a licensed product in a given country where
 sales of a generic equivalent of such licensed product occur in
 such country. Akorn may, at Akorn&amp;#x2019;s expense, act to acquire
 and maintain on the Company&amp;#x2019;s behalf, registrations for
 certain Company trademarks in North America. In addition, Akorn
 may, but is not obligated to, pay any maintenance or other fees
 related to the maintenance of certain patents licensed by the
 Company to Akorn in the event the Company fails to pay any such
 fee.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Historically, the Company has incurred substantial cumulative
 losses and negative cash flows from operations. As of June&amp;#xA0;30,
 2014, the Company&amp;#x2019;s accumulated deficit was $169.6 million
 and its cash and cash equivalents were $2.5 million. Further, the
 Company anticipates that its existing cash and cash equivalent
 balances, together with cash flows from operations, will only be
 adequate to fund its cash requirements through September
 2014.&amp;#xA0;Management&amp;#x2019;s plans include exploring strategic
 alternatives or raising additional financing. These conditions
 raise substantial doubt about the Company&amp;#x2019;s ability to
 continue as a going concern. The financial statements do not
 include any adjustments to reflect the possible future effects
 relating to the recoverability and classification of the recorded
 asset amounts or amounts and classification of liabilities that
 might result from the outcome of this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 These unaudited condensed consolidated financial statements and
 notes should be read in conjunction with the Company&amp;#x2019;s
 audited consolidated financial statements and notes thereto
 included in its Annual Report on Form 10-K for the fiscal year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The preparation of financial statements requires the Company to
 make estimates and assumptions that affect the amounts reported in
 the condensed consolidated financial statements and accompanying
 notes. Actual results could materially differ from those
 estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Warrant Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 In July 2011, the Company issued warrants to purchase shares of the
 Company&amp;#x2019;s common stock in connection with a private placement
 financing transaction. The Company accounted for these warrants as
 a liability measured at fair value due to a provision included in
 the warrant agreements that provides the warrant holders with an
 option to require the Company (or its successor) to purchase their
 warrants for cash in the event of a &amp;#x201C;Fundamental
 Transaction&amp;#x201D; (as defined in the warrant agreements). The
 actual amount of cash required if the mandatory purchase option is
 exercised would be determined using the Black-Scholes Option
 Pricing Model (the &amp;#x201C;Black-Scholes Model&amp;#x201D;) as determined
 in accordance with the terms of the warrant agreements. The fair
 value of the warrant liability is estimated using the Black-Scholes
 Model, which requires inputs such as the remaining term of the
 warrants, share price volatility and risk-free interest rate. These
 assumptions are reviewed on a monthly basis and changes in the
 estimated fair value of the outstanding warrants are recognized
 each reporting period in the Condensed Consolidated Statements of
 Operations under &amp;#x201C;Change in fair value of warrant
 liability.&amp;#x201D;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 Fair value is the price that would be received from selling an
 asset or paid to transfer a liability in an orderly transaction
 between market participants at the measurement date. Fair value is
 estimated by applying the following hierarchy, which prioritizes
 the inputs used to measure fair value into three levels and bases
 the categorization within the hierarchy upon the lowest level of
 input that is available and significant to the fair value
 measurement:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="93%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;1:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Quoted prices in active markets for identical
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level 2:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Observable inputs other than quoted prices in
 active markets for identical assets and liabilities, quoted prices
 for identical or similar assets or liabilities in inactive markets,
 or other inputs that are observable or can be corroborated by
 observable market data for substantially the full term of the
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level 3:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Inputs that are generally unobservable and
 typically reflect management&amp;#x2019;s estimate of assumptions that
 market participants would use in pricing the asset or
 liability.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Company&amp;#x2019;s financial instruments consist mainly of cash
 and cash equivalents, short-term investments, accounts receivable,
 accounts payable and accrued liabilities. Accounts receivable and
 accounts payable are reflected in the accompanying unaudited
 condensed consolidated financial statements at cost, which
 approximates fair value due to the short-term nature of these
 instruments. While the Company believes its valuation methodologies
 are appropriate and consistent with those of other market
 participants, the use of different methodologies or assumptions to
 determine the fair value of certain financial instruments could
 result in a different estimate of fair value at the reporting
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 At June&amp;#xA0;30, 2014, $1.9 million of the Company&amp;#x2019;s cash and
 cash equivalents consisted of Level 1 U.S. Treasury-backed
 government securities or money market funds that are measured at
 fair value on a recurring basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 As discussed above, the fair value of the warrant liability,
 determined using Level 3 criteria, was initially recorded on the
 grant date and remeasured at June&amp;#xA0;30, 2014 using the
 Black-Scholes Model, which requires inputs such as the remaining
 term of the warrants, share price volatility and risk-free interest
 rate. These inputs are subjective and generally require significant
 analysis and judgment to develop. A significant increase (decrease)
 of any of the subjective variables would result in a correlated
 increase (decrease) in the warrant liability and an inverse effect
 on net income (loss).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"&gt;
 The fair value of the warrant liability was estimated using the
 following assumptions, as determined in accordance with the terms
 of the warrant agreements, at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The expected dividend yield was set at zero because the Company has
 never paid cash dividends and has no present intention to pay cash
 dividends. Expected volatility was based on the historical
 volatility of the Company&amp;#x2019;s common stock and was equal to the
 greater of 100% or the 30-day volatility rate. The risk-free
 interest rates were taken from the Daily Federal Yield Curve Rates
 as published by the Federal Reserve and represent the yields on
 actively traded U.S. Treasury securities for a term equal to the
 remaining term of the warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table provides a summary of changes in the fair value
 of the Company&amp;#x2019;s Level 3 financial liabilities for the six
 months ended June&amp;#xA0;30, 2014 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net decrease in fair value of warrant liability on
 remeasurement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;791&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The net decrease in the estimated fair value of the warrant
 liability was recognized as income under &amp;#x201C;Change in fair
 value of warrant liability&amp;#x201D; in the Condensed Consolidated
 Statements of Operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The warrant liability&amp;#x2019;s exposure to market risk will vary
 over time depending on interest rates and the Company&amp;#x2019;s stock
 price. Although the table above reflects the current estimated fair
 value of the warrant liability, it does not reflect the gains or
 losses associated with market exposures, which will depend on
 actual market conditions during the remaining life of the
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 In May 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 No.&amp;#xA0;2014-09 (&amp;#x201C;ASU 2014-09&amp;#x201D;), Revenue from
 Contracts with Customers. The FASB and the International Accounting
 Standards Board (&amp;#x201C;IASB&amp;#x201D;) initiated a joint project to
 clarify the principles for recognizing revenue and developed a
 common revenue recognition standard for U.S. generally accepted
 accounting principles (&amp;#x201C;GAAP&amp;#x2019;) and International
 Financial Reporting Standards (&amp;#x201C;IFRS&amp;#x201D;). Under the
 guidance, an entity should recognize revenue when the entity
 satisfies a performance obligation within a contract at a
 determined transaction price. This update is effective for interim
 and annual reporting periods beginning after December&amp;#xA0;15,
 2016; early adoption is not permitted. The Company does not expect
 the adoption of this standard will materially impact the
 Company&amp;#x2019;s consolidated statement of financial position or
 results of operations.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_2_1">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_1EB79F56-AC8C-4E47-AF97-3037345DAEF4_1_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_929A2C45-E11E-4C4B-ACEC-C146512A639E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company estimates the fair value of stock options using a
 Black-Scholes valuation model using the graded-vesting method with
 the following weighted-average assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 45.5pt"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_7D296C27-CC20-4F05-B2AA-901C4DCBAA5A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table sets forth the computation of basic and diluted
 net income per share:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 116.65pt"&gt;
 (in thousands, except per share data)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,470&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted-average shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Weighted-average shares outstanding for diluted loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7em; TEXT-INDENT: -1em"&gt;
 Basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7em; TEXT-INDENT: -1em"&gt;
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_F5B940D9-BAE4-43BA-9582-77A3833F8037_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Note 5. Non-Recourse Secured Notes Payable&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 In February 2008, the Company&amp;#x2019;s wholly-owned subsidiary,
 Azithromycin Royalty Sub, LLC, (the &amp;#x201C;Subsidiary&amp;#x201D;)
 completed a private placement of $60.0 million in aggregate
 principal amount of the AzaSite Notes, which were non-convertible,
 non-recourse promissory notes due in 2019. The annual interest rate
 on the notes was 16% with interest payable quarterly in arrears.
 The notes were secured by royalties to be paid to the Company by
 Akorn from net sales of AzaSite in the United States. The secured
 notes were non-recourse to InSite Vision Incorporated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 For the quarters ended December&amp;#xA0;31, 2013 and March&amp;#xA0;31,
 2014, the Subsidiary received insufficient royalties to make the
 interest payments in full that were due on the notes. Accordingly,
 an event of default occurred on May&amp;#xA0;15, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On June&amp;#xA0;10, 2014, the Subsidiary and the noteholders entered
 into a Note Purchase Agreement under which the Subsidiary
 repurchased and cancelled the AzaSite Notes for a single payment of
 $6.0 million. As a result of the cancellation, the remaining
 principal on the AzaSite Notes of $41.3 million and accrued
 interest of $2.8 million was extinguished. In addition, the
 Subsidiary wrote-off the remaining balance of $2.1 million in debt
 issuance costs and incurred less than $0.1 million of legal and
 professional fees. In the Condensed Consolidated Statement of Cash
 Flows for the six months ended June&amp;#xA0;30, 2014, the unpaid
 principle of $35.3 million and unpaid interest of $2.8 million less
 the write-off of debt issuance costs of $2.1 million are included
 under &amp;#x201C;Non-cash financing activites &amp;#x2013; Debt
 extinguishment.&amp;#x201D;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The $6.0 million payment to the noteholders was funded by Akorn in
 return for a lower royalty on net sales of AzaSite in North
 America.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 For the three and six months ended June&amp;#xA0;30, 2014, the gain on
 the extinguishment of debt was $36.0 million and represented basic
 and diluted net income per share of $0.27 for both periods.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_9AE9E9DB-1DC8-43DF-844D-8D504217A9F0_1_1">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="3" id="id_3815551_E72536B2-D980-40D3-9456-2F6D2D1757EE_1_0">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_2F6A4DB2-8242-4A6B-A877-FF4227445BA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 7. Legal Proceedings&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The Company is subject to various claims and legal actions during
 the ordinary course of its business.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 In April 2011, the Company received a Notice Letter that Sandoz,
 Inc. or Sandoz, has filed an Abbreviated New Drug Application, or
 ANDA, with the U.S. Food and Drug Administration (FDA) seeking
 marketing approval for a 1% azithromycin ophthalmic solution, or
 the Sandoz Product, prior to the expiration of the five U.S.
 patents listed in the Orange Book for AzaSite, which include four
 of our patents and one patent&amp;#xA0;licensed to us by
 Pfizer.&amp;#xA0;In the paragraph IV Certification accompanying the
 Sandoz ANDA filing, Sandoz&amp;#xA0;alleges that the claims of the
 Orange Book listed patents are invalid, unenforceable and/or will
 not be infringed upon by the Sandoz Product.&amp;#xA0;On May&amp;#xA0;26,
 2011, we, Merck and Pfizer filed a patent infringement lawsuit
 against Sandoz and related entities. The plaintiff companies agreed
 that Merck would take the lead in prosecuting this lawsuit. Before
 the trial, the patents involved in the litigation were limited to
 the one Pfizer patent and three of our patents. On October&amp;#xA0;4,
 2013, the United States District Court for the District of New
 Jersey entered a Final Judgment in favor of us and the other
 plaintiffs finding all the asserted claims of the patents in the
 litigation valid and infringed by Sandoz and related entities. The
 Court Order specified that the effective date of any FDA approval
 of a Sandoz ANDA for generic 1% azithromycin ophthalmic solution
 products would be no earlier than the expiration date of the
 patents in the litigation. On November&amp;#xA0;4, 2013, Sandoz filed
 an appeal of this decision to the United States Court of Appeals
 for the Federal Circuit. On November&amp;#xA0;15, 2013, Akorn acquired
 Inspire from Merck, and as such, acquired the rights to AzaSite in
 North America. Akorn has taken the lead in prosecuting this
 lawsuit. We and the other plaintiffs intend to vigorously contest
 any Sandoz assertions that these patents should have been found not
 infringed, invalid or unenforceable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 In May 2013, the Company received a Notice Letter that Mylan
 Pharmaceuticals, Inc. or Mylan, has filed an ANDA with the FDA
 seeking marketing approval for a 1% azithromycin ophthalmic
 solution, or the Mylan Product, prior to the expiration of the U.S.
 patents listed in the Orange Book for AzaSite, which include three
 of our patents and one patent licensed to us by Pfizer.&amp;#xA0;In the
 paragraph IV Certification accompanying the Mylan ANDA filing,
 Mylan alleges that the claims of the Orange Book listed patents are
 invalid, unenforceable and/or will not be infringed upon by the
 Mylan Product.&amp;#xA0;On June&amp;#xA0;14, 2013, we, Merck and Pfizer
 filed a patent infringement lawsuit against Mylan and a related
 entity.&amp;#xA0;On November&amp;#xA0;15, 2013, Akorn acquired Inspire from
 Merck, and as such, acquired the rights to AzaSite in North
 America. The plaintiff companies have agreed that Akorn will take
 the lead in prosecuting this lawsuit. The filing of this lawsuit
 triggered an automatic stay, or bar, of the FDA&amp;#x2019;s approval of
 the ANDA for up to 30 months or until a final district court
 decision of the infringement lawsuit, whichever comes first. We and
 the other plaintiffs intend to vigorously enforce our patent rights
 relating to AzaSite and vigorously contest any Mylan assertions
 that these patents are invalid or unenforceable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On January&amp;#xA0;3, 2013, certain plaintiffs filed a complaint in
 circuit court in Fayette County, Kentucky against Bausch&amp;#xA0;&amp;amp;
 Lomb and the Company alleging that they were injured when treated
 with the Bausch&amp;#xA0;&amp;amp; Lomb product Besivance following a
 photorefractive keratectomy. In February 2013, Bausch&amp;#xA0;&amp;amp;
 Lomb removed the case to the United States District Court for the
 Eastern District of Kentucky. The Company moved to dismiss for lack
 of jurisdiction and in January 2014, the plaintiffs filed a
 response conceding to the Company&amp;#x2019;s motion to dismiss for
 lack of personal jurisdiction. On March&amp;#xA0;7, 2014, the matter
 was taken off docket by the District Court. The Company
 subsequently received a complete release of all claims.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On July&amp;#xA0;24, 2014, Karin Stiens filed a complaint against
 Bausch&amp;#xA0;&amp;amp; Lomb, Dr.&amp;#xA0;Lance Ferguson and the Company
 (Fayette (Kentucky) Circuit Court Civil Action No.&amp;#xA0;14-CI-2829)
 alleging that she suffered ophthalmological damage when
 Dr.&amp;#xA0;Ferguson engaged in off-label use of Besivance in a
 photorefractive keratectomy procedure as a prophylactic antibiotic.
 The plaintiff alleges that Bausch&amp;#xA0;&amp;amp; Lomb and the Company
 negligently tested, marketed and distributed Besivance, and
 negligently informed medical providers and consumers about
 Besivance. The complaint contains no facts supporting these general
 allegations, no facts supporting the plaintiff&amp;#x2019;s claim of
 permanent injuries and no allegations asserting Kentucky
 jurisdiction over the Company. The plaintiff has not pleaded any
 specific amount in damages. The Company is investigating the
 plaintiff&amp;#x2019;s allegations. The Company&amp;#x2019;s answer is due by
 August&amp;#xA0;18, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 There are currently no other claims or legal actions that would
 have a material adverse impact on our financial position,
 operations or potential performance.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_BDA8DB6C-BF72-4352-9FB4-2EA5504B980B_2001_3">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_BEDF2F78-1E2C-4595-99A6-D22EB3458ADD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Note 3. Net Income per Share&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 Basic net income per share has been computed using the
 weighted-average number of common shares outstanding during the
 period. Dilutive net income per share was computed using the sum of
 the weighted average number of common shares outstanding and the
 potential number of dilutive common shares outstanding during the
 period. Potential common shares consist of the shares issuable upon
 exercise of stock options and warrants. Potentially dilutive
 securities have been excluded from the computation of diluted net
 income per share in 2014 and 2013 as their inclusion would be
 anti-dilutive. For the three months ended June&amp;#xA0;30, 2014 and
 2013, respectively, 34,449,287 and 30,699,052 options and warrants
 were excluded from the calculation of diluted net income per share
 because the effect was anti-dilutive. For the six months ended
 June&amp;#xA0;30, 2014 and 2013, respectively, 34,067,149 and
 30,706,276 options and warrants were excluded from the calculation
 of diluted net income per share because the effect was
 anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table sets forth the computation of basic and diluted
 net income per share:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 116.65pt"&gt;
 (in thousands, except per share data)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,470&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted-average shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Weighted-average shares outstanding for diluted loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7em; TEXT-INDENT: -1em"&gt;
 Basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7em; TEXT-INDENT: -1em"&gt;
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_9AE9E9DB-1DC8-43DF-844D-8D504217A9F0_1_2">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_FD04F0F3-54F9-42EE-B284-BA331062181A_5001_5">70944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_917F0F1A-2C37-4E28-A372-A19F8905857B_3_0">34067149</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_468287DC-5C47-4DA7-9A94-928C2976B976_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Stock-based compensation included in expense line items in the
 Condensed Consolidated Statements of Operations for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_A9A4880A-4165-4470-BBE0-33AC0C954FC7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements requires the Company to
 make estimates and assumptions that affect the amounts reported in
 the condensed consolidated financial statements and accompanying
 notes. Actual results could materially differ from those
 estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_118E95CB-9849-44B8-82DD-0774224065BC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net income per share has been computed using the
 weighted-average number of common shares outstanding during the
 period. Dilutive net income per share was computed using the sum of
 the weighted average number of common shares outstanding and the
 potential number of dilutive common shares outstanding during the
 period. Potential common shares consist of the shares issuable upon
 exercise of stock options and warrants. Potentially dilutive
 securities have been excluded from the computation of diluted net
 income per share in 2014 and 2013 as their inclusion would be
 anti-dilutive. For the three months ended June&amp;#xA0;30, 2014 and
 2013, respectively, 34,449,287 and 30,699,052 options and warrants
 were excluded from the calculation of diluted net income per share
 because the effect was anti-dilutive.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_84CA6804-D58A-48E3-8CC4-DC1AB1A77E24_5001_4">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_4FBFBC85-0FEB-4272-AF30-695DC54394C6_1_0">2777000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_BB400BD9-7196-495C-B3F0-F77061950A8B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 8. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company evaluated subsequent events through the date on which
 the financial statements were issued and determined that there were
 no subsequent events that required adjustments or disclosures to
 the financial statements for the quarter ended June&amp;#xA0;30,
 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_D55610C5-2DA4-47DB-A11F-99C10D4F056A_1_1">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_20">131951000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_E0BFF41F-C032-44A5-9C8F-3FCBEE1BC1FB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The accompanying unaudited condensed consolidated financial
 statements include the accounts of InSite Vision Incorporated
 (&amp;#x201C;InSite&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) and its
 wholly-owned subsidiaries. All significant intercompany accounts
 and transactions have been eliminated in the preparation of the
 condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The accompanying unaudited condensed consolidated financial
 statements have been prepared in accordance with accounting
 principles generally accepted in the United States (&amp;#x201C;U.S.
 GAAP&amp;#x201D;) for interim financial information. Accordingly, they
 do not include all of the information and footnotes required for
 complete financial statements. In the opinion of management, all
 adjustments, consisting of normal recurring adjustments, considered
 necessary for a fair presentation of the Company&amp;#x2019;s financial
 results and financial condition have been included. Operating
 results for the three and six months ended June&amp;#xA0;30, 2014 are
 not necessarily indicative of the results that may be expected for
 any future period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Company operates in one segment using one measure of
 profitability to manage its business.&amp;#xA0;All of the
 Company&amp;#x2019;s long-lived assets are located in the United States.
 Revenues are primarily royalties from the North American license
 (the &amp;#x201C;Akorn License&amp;#x201D;) of AzaSite to Akorn, Inc.
 (&amp;#x201C;Akorn&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On June&amp;#xA0;10, 2014, the Company entered into the Third Amendment
 to License Agreement (the &amp;#x201C;Amendment&amp;#x201D;) with Akorn to
 amend the Akorn License. Under the Amendment, Akorn paid the
 Company an amendment fee of $6.0 million in return for a lower
 royalty on net sales of AzaSite in North America. The $6.0 million
 was used by the Company to repurchase and cancel the AzaSite Notes
 (for further discussion, see Note 5). Effective April&amp;#xA0;1, 2014,
 for annual net sales of AzaSite, the royalty is (1)&amp;#xA0;8.0% on
 net sales less than $20.0 million, subject to increase to 9.0% in
 the event that Akorn enters into certain settlements with third
 parties seeking to launch generic versions of AzaSite,
 (2)&amp;#xA0;12.5% on net sales greater than or equal to $20.0 million
 and less than or equal to $50.0 million and (3)&amp;#xA0;15.0% on net
 sales in excess of $50.0 million. For annual net sales of AzaSite
 Xtra, the royalty would be 12.5% on net sales less than $30.0
 million and 15.0% on net sales greater than or equal to $30.0
 million. The Company waived any right to consent to any settlements
 regarding AzaSite (for further discussion, see Note 7) and agreed
 to cooperate to effectuate any such settlement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Amendment further provides that in the event AzaSite Xtra has
 received regulatory approval and has been commercially launched by
 Akorn, as to any calendar quarter, Akorn would not be obligated to
 pay any royalties as to a licensed product in a given country where
 sales of a generic equivalent of such licensed product occur in
 such country. Akorn may, at Akorn&amp;#x2019;s expense, act to acquire
 and maintain on the Company&amp;#x2019;s behalf, registrations for
 certain Company trademarks in North America. In addition, Akorn
 may, but is not obligated to, pay any maintenance or other fees
 related to the maintenance of certain patents licensed by the
 Company to Akorn in the event the Company fails to pay any such
 fee.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Historically, the Company has incurred substantial cumulative
 losses and negative cash flows from operations. As of June&amp;#xA0;30,
 2014, the Company&amp;#x2019;s accumulated deficit was $169.6 million
 and its cash and cash equivalents were $2.5 million. Further, the
 Company anticipates that its existing cash and cash equivalent
 balances, together with cash flows from operations, will only be
 adequate to fund its cash requirements through September
 2014.&amp;#xA0;Management&amp;#x2019;s plans include exploring strategic
 alternatives or raising additional financing. These conditions
 raise substantial doubt about the Company&amp;#x2019;s ability to
 continue as a going concern. The financial statements do not
 include any adjustments to reflect the possible future effects
 relating to the recoverability and classification of the recorded
 asset amounts or amounts and classification of liabilities that
 might result from the outcome of this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 These unaudited condensed consolidated financial statements and
 notes should be read in conjunction with the Company&amp;#x2019;s
 audited consolidated financial statements and notes thereto
 included in its Annual Report on Form 10-K for the fiscal year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_BDA8DB6C-BF72-4352-9FB4-2EA5504B980B_2001_4">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_0F0CC3FE-449A-44FD-9D99-731CA76CE7AB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Note 2. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;u&gt;Equity Incentive Program&lt;/u&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 In 2007, the Company&amp;#x2019;s stockholders approved the
 Company&amp;#x2019;s 2007 Performance Incentive Plan (the &amp;#x201C;2007
 Plan&amp;#x201D;), which provides for grants of options and other
 equity-based awards to the Company&amp;#x2019;s employees, directors and
 consultants. Options granted under this plan, and its predecessor
 plan, expire 10 years after the date of grant and become
 exercisable at such times and under such conditions as determined
 by the Company&amp;#x2019;s Board of Directors (generally, with 25%
 vesting after one year and the balance vesting on a daily basis
 over the next three years of service). Upon termination of the
 optionee&amp;#x2019;s service, unvested options terminate and vested
 options generally expire three months thereafter, if not exercised.
 Only nonqualified stock options have been granted under these plans
 to date. On January&amp;#xA0;1 of each calendar year during the term of
 the 2007 Plan, the shares of common stock available for issuance
 under the 2007 Plan will be increased by the lesser of (i)&amp;#xA0;2%
 of the total outstanding shares of common stock on December&amp;#xA0;31
 of the preceding calendar year and (ii)&amp;#xA0;3,000,000 shares. On
 January&amp;#xA0;1, 2014, the shares of common stock available for
 issuance under the 2007 Plan increased by 2,639,020 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;u&gt;Stock-based Compensation&lt;/u&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The Company&amp;#x2019;s stock-based compensation cost is measured at
 the grant date, based on the fair value of the award, and is
 recognized as expense over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The effect of recording stock-based compensation for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation expense by type of award:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Employee stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Scientific Advisory Board stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Stock-based compensation included in expense line items in the
 Condensed Consolidated Statements of Operations for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 During the six months ended June&amp;#xA0;30, 2014 and 2013, the
 Company granted options to purchase 2,777,000 and 3,356,847 shares
 of common stock, respectively, with an estimated total grant date
 fair value of $555,000 and $749,000, respectively. Based on the
 Company&amp;#x2019;s historical experience of option cancellations and
 estimates of future forfeiture rates, the Company has assumed an
 annualized forfeiture rate of 10% for its options for all periods
 disclosed. Accordingly, for the quarters ended June&amp;#xA0;30, 2014
 and 2013, the Company estimated that the stock-based compensation
 for the awards not expected to vest was $276,000 and $332,000,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 As of June&amp;#xA0;30, 2014, unrecorded deferred stock-based
 compensation balance related to stock options was $1.2 million and
 will be recognized over an estimated weighted-average amortization
 period of 2.4 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;u&gt;Valuation assumptions&lt;/u&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The Company estimates the fair value of stock options using a
 Black-Scholes valuation model using the graded-vesting method with
 the following weighted-average assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 45.5pt"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The expected dividend yield was set at zero because the Company has
 never paid cash dividends and has no present intention to pay cash
 dividends. Expected volatility was based on the historical
 volatility of the Company&amp;#x2019;s common stock and the expected
 moderation in future volatility over the period commensurate with
 the expected life of the options and other factors. The risk-free
 interest rates were taken from the Daily Federal Yield Curve Rates
 as of the grant dates as published by the Federal Reserve and
 represent the yields on actively traded U.S. Treasury securities
 for terms equal to the expected term of the options. The expected
 term calculation was based on the terms utilized by the
 Company&amp;#x2019;s peers, observed historical option exercise behavior
 and forfeitures of options by the Company&amp;#x2019;s employees. No
 options were granted during the three months ended June&amp;#xA0;30,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following is a summary of stock option activity for the
 indicated periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number of&lt;br /&gt;
 shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-Average&lt;br /&gt;
 Remaining&amp;#xA0;Contractual&lt;br /&gt;
 Term (Years)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;br /&gt;
 (in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,097,984&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,777,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(70,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(146,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,657,911&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested and expected to vest at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,016,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,894,583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 At June&amp;#xA0;30, 2014, the Company had 4,600,447 shares of common
 stock available for grant or issuance under its 2007 Plan. The
 weighted average grant date fair value of options granted during
 the six months ended June&amp;#xA0;30, 2014 and 2013 was $0.20 and
 $0.22 per share, respectively. No options were exercised during the
 six months ended June&amp;#xA0;30, 2014 and 2013.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_69123FBE-65E2-4358-9F13-D127FE52119B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 No.&amp;#xA0;2014-09 (&amp;#x201C;ASU 2014-09&amp;#x201D;), Revenue from
 Contracts with Customers. The FASB and the International Accounting
 Standards Board (&amp;#x201C;IASB&amp;#x201D;) initiated a joint project to
 clarify the principles for recognizing revenue and developed a
 common revenue recognition standard for U.S. generally accepted
 accounting principles (&amp;#x201C;GAAP&amp;#x2019;) and International
 Financial Reporting Standards (&amp;#x201C;IFRS&amp;#x201D;). Under the
 guidance, an entity should recognize revenue when the entity
 satisfies a performance obligation within a contract at a
 determined transaction price. This update is effective for interim
 and annual reporting periods beginning after December&amp;#xA0;15,
 2016; early adoption is not permitted. The Company does not expect
 the adoption of this standard will materially impact the
 Company&amp;#x2019;s consolidated statement of financial position or
 results of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="Segment" decimals="INF" id="id_3815551_3B849C0D-30BF-41C6-90A1-1070B536DC48_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_0152C9A6-F421-4D9F-A96D-C053DCAB6B31_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"&gt;
 The fair value of the warrant liability was estimated using the
 following assumptions, as determined in accordance with the terms
 of the warrant agreements, at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_1EB79F56-AC8C-4E47-AF97-3037345DAEF4_1_3">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_DA3DA98E-46E6-4CC5-979A-0EDEF06C37CE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 Fair value is the price that would be received from selling an
 asset or paid to transfer a liability in an orderly transaction
 between market participants at the measurement date. Fair value is
 estimated by applying the following hierarchy, which prioritizes
 the inputs used to measure fair value into three levels and bases
 the categorization within the hierarchy upon the lowest level of
 input that is available and significant to the fair value
 measurement:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="93%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;1:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Quoted prices in active markets for identical
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level 2:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Observable inputs other than quoted prices in
 active markets for identical assets and liabilities, quoted prices
 for identical or similar assets or liabilities in inactive markets,
 or other inputs that are observable or can be corroborated by
 observable market data for substantially the full term of the
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level 3:&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Inputs that are generally unobservable and
 typically reflect management&amp;#x2019;s estimate of assumptions that
 market participants would use in pricing the asset or
 liability.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The Company&amp;#x2019;s financial instruments consist mainly of cash
 and cash equivalents, short-term investments, accounts receivable,
 accounts payable and accrued liabilities. Accounts receivable and
 accounts payable are reflected in the accompanying unaudited
 condensed consolidated financial statements at cost, which
 approximates fair value due to the short-term nature of these
 instruments. While the Company believes its valuation methodologies
 are appropriate and consistent with those of other market
 participants, the use of different methodologies or assumptions to
 determine the fair value of certain financial instruments could
 result in a different estimate of fair value at the reporting
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 At June&amp;#xA0;30, 2014, $1.9 million of the Company&amp;#x2019;s cash and
 cash equivalents consisted of Level 1 U.S. Treasury-backed
 government securities or money market funds that are measured at
 fair value on a recurring basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 As discussed above, the fair value of the warrant liability,
 determined using Level 3 criteria, was initially recorded on the
 grant date and remeasured at June&amp;#xA0;30, 2014 using the
 Black-Scholes Model, which requires inputs such as the remaining
 term of the warrants, share price volatility and risk-free interest
 rate. These inputs are subjective and generally require significant
 analysis and judgment to develop. A significant increase (decrease)
 of any of the subjective variables would result in a correlated
 increase (decrease) in the warrant liability and an inverse effect
 on net income (loss).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"&gt;
 The fair value of the warrant liability was estimated using the
 following assumptions, as determined in accordance with the terms
 of the warrant agreements, at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The expected dividend yield was set at zero because the Company has
 never paid cash dividends and has no present intention to pay cash
 dividends. Expected volatility was based on the historical
 volatility of the Company&amp;#x2019;s common stock and was equal to the
 greater of 100% or the 30-day volatility rate. The risk-free
 interest rates were taken from the Daily Federal Yield Curve Rates
 as published by the Federal Reserve and represent the yields on
 actively traded U.S. Treasury securities for a term equal to the
 remaining term of the warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table provides a summary of changes in the fair value
 of the Company&amp;#x2019;s Level 3 financial liabilities for the six
 months ended June&amp;#xA0;30, 2014 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net decrease in fair value of warrant liability on
 remeasurement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;791&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The net decrease in the estimated fair value of the warrant
 liability was recognized as income under &amp;#x201C;Change in fair
 value of warrant liability&amp;#x201D; in the Condensed Consolidated
 Statements of Operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The warrant liability&amp;#x2019;s exposure to market risk will vary
 over time depending on interest rates and the Company&amp;#x2019;s stock
 price. Although the table above reflects the current estimated fair
 value of the warrant liability, it does not reflect the gains or
 losses associated with market exposures, which will depend on
 actual market conditions during the remaining life of the
 warrants.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_21">282000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_1">6000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_22">-5000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_11">-1007000</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_33">1000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_3815551_4FBFBC85-0FEB-4272-AF30-695DC54394C6_1_1">555000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_14">894000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_12">35999000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_25">6000000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:InterestPaid contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_32">1018000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_10">-725000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_5">7502000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_12">86000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_11">-1216000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherSalesRevenueNet contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_4">104000</us-gaap:OtherSalesRevenueNet>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_2">1398000</us-gaap:RoyaltyRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_15">32470000</us-gaap:NetIncomeLoss>
  <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_6">35999000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_16">95000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_26">-6000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_35">36047000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_15">318000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_8">3340000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_7">462000</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromInterestReceived contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_31">1000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:AmortizationOfLeaseIncentives contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_5">92000</us-gaap:AmortizationOfLeaseIncentives>
  <us-gaap:CostOfServicesLicensesAndServices contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_9">296000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_27">-776000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_23">4718000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_17">2003000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_18">993000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_1866947F-02F8-491C-A334-0211878D150C_3001_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_14">-994000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_13">148000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_3">165000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_52FD4026-C513-4ED3-963A-AA0B25F23216_1_4">185000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_3_2">462000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_7">5082000</us-gaap:ResearchAndDevelopmentExpense>
  <insv:CommonStockAvailableForIssuancePercentageOfOutstandingStock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="INF" id="id_3815551_A5D0F684-7AC8-40CA-9F0A-8228514A00A2_1_0">0.02</insv:CommonStockAvailableForIssuancePercentageOfOutstandingStock>
  <insv:StockBasedCompensationNotExpectedToVest contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_3815551_7A841DB2-E532-4E13-BF2A-EC27D7A386D7_1_1">276000</insv:StockBasedCompensationNotExpectedToVest>
  <insv:InterestExpenseAndOtherNet contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_13">3207000</insv:InterestExpenseAndOtherNet>
  <insv:CommonStockSharesAvailableForIssuanceOutstanding contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_A5D0F684-7AC8-40CA-9F0A-8228514A00A2_1_1">3000000</insv:CommonStockSharesAvailableForIssuanceOutstanding>
  <insv:WarrantyLiabilityDisclosureTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_4789F938-F357-459A-8E25-B694FC63F65F_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 4. Warrant Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2011, the Company completed a private placement financing
 transaction in which it sold shares of its common stock and
 warrants to purchase shares of its common stock. The Company sold a
 total of 36,978,440 shares of common stock, at a price of $0.60 per
 share, and issued warrants to purchase up to 14,791,376 shares of
 common stock. The warrants are exercisable at $0.75 per share and
 expire five years from the date of issuance. The private placement
 resulted in $22.2 million in gross proceeds and approximately $20.4
 million in net proceeds to the Company after deducting placement
 agent fees, legal, accounting and other costs associated with the
 transaction. The Company used the net proceeds of the transaction
 to fund clinical trials and for general corporate purposes,
 including working capital.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As discussed in Note 1, the warrants issued in July 2011 include a
 provision that provides the warrant holders with an option to
 require the Company (or its successor) to purchase the warrants for
 cash in an amount equal to the Black-Scholes value in the event of
 a &amp;#x201C;Fundamental Transaction&amp;#x201D; (as defined in the warrant
 agreements). Accordingly, the fair value of the warrants at the
 issuance date was estimated using the Black-Scholes Model, as
 determined in accordance with the terms of the warrant agreements,
 and the Company recorded a warrant liability of $6.4 million in
 July 2011 and remeasured to $1.7 million and $0.8 million at
 December&amp;#xA0;31, 2013 and June&amp;#xA0;30, 2014, respectively. The
 Company recorded decreases to the warrant liability of $0.3 million
 and $0.9 million for the three and six months ended June&amp;#xA0;30,
 2014, respectively, which were recognized as income in the
 Company&amp;#x2019;s Condensed Consolidated Statement of Operations.
 Additional disclosures regarding the assumptions used in
 calculating the fair value of the warrant liability are included in
 Note 1.&lt;/p&gt;
 &lt;/div&gt;</insv:WarrantyLiabilityDisclosureTextBlock>
  <insv:BalanceOptionsVestedInDailyBasis contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_1EB79F56-AC8C-4E47-AF97-3037345DAEF4_1_2">P3Y</insv:BalanceOptionsVestedInDailyBasis>
  <insv:CommonStockSharesAnnualizedForfeitureRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="2" id="id_3815551_7A841DB2-E532-4E13-BF2A-EC27D7A386D7_1_0">0.10</insv:CommonStockSharesAnnualizedForfeitureRate>
  <insv:CostOfSalesAndServicesIncludingOperatingExpenses contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_3_10">8718000</insv:CostOfSalesAndServicesIncludingOperatingExpenses>
  <insv:WarrantLiabilityPolicyTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_6F5FD734-A112-4EAD-A56A-8042F4DFE402_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Warrant Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In July 2011, the Company issued warrants to purchase shares of the
 Company&amp;#x2019;s common stock in connection with a private placement
 financing transaction. The Company accounted for these warrants as
 a liability measured at fair value due to a provision included in
 the warrant agreements that provides the warrant holders with an
 option to require the Company (or its successor) to purchase their
 warrants for cash in the event of a &amp;#x201C;Fundamental
 Transaction&amp;#x201D; (as defined in the warrant agreements). The
 actual amount of cash required if the mandatory purchase option is
 exercised would be determined using the Black-Scholes Option
 Pricing Model (the &amp;#x201C;Black-Scholes Model&amp;#x201D;) as determined
 in accordance with the terms of the warrant agreements. The fair
 value of the warrant liability is estimated using the Black-Scholes
 Model, which requires inputs such as the remaining term of the
 warrants, share price volatility and risk-free interest rate. These
 assumptions are reviewed on a monthly basis and changes in the
 estimated fair value of the outstanding warrants are recognized
 each reporting period in the Condensed Consolidated Statements of
 Operations under &amp;#x201C;Change in fair value of warrant
 liability.&amp;#x201D;&lt;/p&gt;
 &lt;/div&gt;</insv:WarrantLiabilityPolicyTextBlock>
  <insv:OptionsVestedPerformanceIncentivePlanOneYearInPercentage contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" unitRef="pure" decimals="2" id="id_3815551_1EB79F56-AC8C-4E47-AF97-3037345DAEF4_1_1">0.25</insv:OptionsVestedPerformanceIncentivePlanOneYearInPercentage>
  <insv:CommonStockWarrantsDisclosureTextBlock contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0" id="id_3815551_C933C827-1468-49B7-BE6B-DE3AA69B3F1C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 6. Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The following table shows outstanding warrants as of June&amp;#xA0;30,
 2014, all of which were issued in the July 2011 private placement
 financing transaction. All of the outstanding warrants have
 cashless exercise provisions in the event the registration
 statement registering the resale of the shares of common stock
 issuable upon exercise of the warrants is not effective or the
 prospectus forming a part of the registration statement is not
 current. All warrants are exercisable for common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 37.5pt"&gt;
 Date Issued&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Warrant&amp;#xA0;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Expiration&amp;#xA0;Date&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Potential&amp;#xA0;Proceeds&amp;#xA0;if&lt;br /&gt;
 Exercised for Cash&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 July&amp;#xA0;18, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,791,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;July&amp;#xA0;18,&amp;#xA0;2016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,093,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</insv:CommonStockWarrantsDisclosureTextBlock>
  <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581" id="id_3815551_FA816831-831D-46A1-8744-B3ABC6667510_1001_1">2011-07-18</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4AA0F5F3-C8D8-49D0-8D91-8F8F83A29386_1005_2">-894000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <insv:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581" id="id_3815551_FA816831-831D-46A1-8744-B3ABC6667510_1001_4">July 18, 2016</insv:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_1874581A-7311-4C90-B579-2E205F437B68_1001_3">1.259</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_1874581A-7311-4C90-B579-2E205F437B68_1001_0">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1001_0">0.005</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1001_1">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:DividendsCash contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="0" id="id_3815551_1874581A-7311-4C90-B579-2E205F437B68_1001_1">0</us-gaap:DividendsCash>
  <insv:DurationOfVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" id="id_3815551_1874581A-7311-4C90-B579-2E205F437B68_1001_4">P30D</insv:DurationOfVolatilityRate>
  <insv:FairValueAssumptionsExpectedVolatilityRateDescription contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798" id="id_3815551_1874581A-7311-4C90-B579-2E205F437B68_1001_2">Expected  volatility was based on the historical volatility of the Company&apos;s common stock  and was equal to the greater of 100% or the 30-day volatility rate.</insv:FairValueAssumptionsExpectedVolatilityRateDescription>
  <insv:DeterminationOfRoyaltyIncomeDescription contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_711809x1077186" id="id_3815551_20CBCF58-99CE-4886-BB8D-B7F5EDC51C53_2002_1">(1) 8.0% on net sales less than $20.0 million, subject  to increase to 9.0% in the event that Akorn enters into certain settlements with  third parties seeking to launch generic versions of AzaSite, (2) 12.5% on net  sales greater than or equal to $20.0 million and less than or equal to $50.0  million and (3) 15.0% on net sales in excess of $50.0 million.</insv:DeterminationOfRoyaltyIncomeDescription>
  <insv:DeterminationOfRoyaltyIncomeDescription contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_711809x1077187" id="id_3815551_20CBCF58-99CE-4886-BB8D-B7F5EDC51C53_3002_3">The royalty would be 12.5% on net sales less than $30.0  million and 15.0% on net sales greater than or equal to $30.0 million.</insv:DeterminationOfRoyaltyIncomeDescription>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_1003_1">276000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_2003_0">186000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x1078421" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_1003_3">35300000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:DebtIssuanceCosts contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x1078421" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_1003_5">2100000</us-gaap:DebtIssuanceCosts>
  <insv:ExtinguishmentOfDebtInterestAmount contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x1078421" unitRef="iso4217_USD" decimals="-5" id="id_3815551_323928F3-6EF4-4976-9869-62928FA79321_1003_4">2800000</insv:ExtinguishmentOfDebtInterestAmount>
  <us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x843611" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_11B9F871-1D89-406D-B2D3-8623C709E92A_1002_1">0.27</us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_11B9F871-1D89-406D-B2D3-8623C709E92A_1002_0">36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_715329x708980" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_1003_0">466000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_181_20140630_0_715329x739390" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_2003_1">-4000</us-gaap:AllocatedShareBasedCompensationExpense>
  <insv:PeriodForFiling contextRef="eol_PE5378----1410-Q0004_STD_2_20130614_0_711502x716112" id="id_3815551_F7EEE097-EA8C-444F-9A9A-E6BC5438E000_1_0">P30M</insv:PeriodForFiling>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE5378----1410-Q0004_STD_31_20110731_0" unitRef="iso4217_USD" decimals="-5" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_1_6">20400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <insv:ProceedsFromIssuanceOfPrivatePlacementGross contextRef="eol_PE5378----1410-Q0004_STD_31_20110731_0" unitRef="iso4217_USD" decimals="-5" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_1_5">22200000</insv:ProceedsFromIssuanceOfPrivatePlacementGross>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE5378----1410-Q0004_STD_31_20110731_0_709650x713713" unitRef="shares" decimals="INF" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_1001_0">36978440</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <insv:ExpirationPeriodOfWarrants contextRef="eol_PE5378----1410-Q0004_STD_31_20110731_0_709650x715581" id="id_3815551_9D20EE96-B3BE-4A25-8615-5AA0DF6866BC_2001_4">P5Y</insv:ExpirationPeriodOfWarrants>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_365_20131231_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1002_3">1.000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5378----1410-Q0004_STD_365_20131231_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1002_2">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5378----1410-Q0004_STD_365_20131231_0_709650x715581_712546x711349_715757x715798" unitRef="pure" decimals="3" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1002_0">0.008</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE5378----1410-Q0004_STD_365_20131231_0_709650x715581_712546x711349_715757x715798" id="id_3815551_49DB6E5D-8DD4-4A46-960B-6481ED43D3EB_1002_1">P2Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_17">0.09</us-gaap:EarningsPerShareBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_1_0">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_18">0.09</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_21">132512000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_1_3">0.906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_6C3362BF-5115-4278-A06A-AF1434ABB033_2_5">561000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_1_1">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="pure" decimals="3" id="id_3815551_B9C52338-2C2A-43AA-B6E6-AC62C5DE0C11_1_2">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="shares" decimals="INF" id="id_3815551_917F0F1A-2C37-4E28-A372-A19F8905857B_2_0">30699052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_20">131951000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_14">173000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
  <us-gaap:Revenues contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_5">19240000</us-gaap:Revenues>
  <us-gaap:ContractsRevenue contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_3">14490000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_11">13972000</us-gaap:OperatingIncomeLoss>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_2">4750000</us-gaap:RoyaltyRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_15">12116000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_8">1624000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfServicesLicensesAndServices contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_9">167000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_2_2">212000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_7">3477000</us-gaap:ResearchAndDevelopmentExpense>
  <insv:InterestExpenseAndOtherNet contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_13">2029000</insv:InterestExpenseAndOtherNet>
  <insv:CostOfSalesAndServicesIncludingOperatingExpenses contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_2_10">5268000</insv:CostOfSalesAndServicesIncludingOperatingExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_1002_1">136000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_2002_0">76000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0_715329x708980" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_1002_0">210000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20130630_0_715329x739390" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_2002_1">2000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_17">0.28</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_18">0.28</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_21">131951000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_917F0F1A-2C37-4E28-A372-A19F8905857B_1_0">34449287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="shares" decimals="INF" id="id_3815551_E477445C-080A-4979-8422-95CE24BEDFBC_1_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_20">131951000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_1">6000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_14">314000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_12">35999000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:Revenues contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_5">6349000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_11">2256000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherSalesRevenueNet contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_4">97000</us-gaap:OtherSalesRevenueNet>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_2">252000</us-gaap:RoyaltyRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_15">37149000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_8">1400000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfServicesLicensesAndServices contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_9">158000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_1_2">210000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_7">2535000</us-gaap:ResearchAndDevelopmentExpense>
  <insv:InterestExpenseAndOtherNet contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_13">1420000</insv:InterestExpenseAndOtherNet>
  <insv:CostOfSalesAndServicesIncludingOperatingExpenses contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_3815551_4E458A2F-312C-4634-9DDC-D44A16711F57_1_10">4093000</insv:CostOfSalesAndServicesIncludingOperatingExpenses>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_709650x715581" unitRef="iso4217_USD" decimals="-5" id="id_3815551_4AA0F5F3-C8D8-49D0-8D91-8F8F83A29386_1004_1">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_1001_1">129000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3815551_9B7CE4F0-F3BC-4262-B458-E4C9786A25F6_2001_0">81000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_714750x843611" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3815551_11B9F871-1D89-406D-B2D3-8623C709E92A_1001_1">0.27</us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_714750x843611" unitRef="iso4217_USD" decimals="-5" id="id_3815551_11B9F871-1D89-406D-B2D3-8623C709E92A_1001_0">36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_715329x708980" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_1001_0">211000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5378----1410-Q0004_STD_91_20140630_0_715329x739390" unitRef="iso4217_USD" decimals="-3" id="id_3815551_A930246B-7549-4CB4-843F-0203B57FE318_2001_1">-1000</us-gaap:AllocatedShareBasedCompensationExpense>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_715329x739390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">insv:ScientificAdvisoryBoardStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_715329x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_714750x843611">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">insv:NotePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20130630_0_715329x739390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">insv:ScientificAdvisoryBoardStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20130630_0_715329x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20130630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20130630_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_365_20131231_0_709650x715581_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_31_20110731_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_31_20110731_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_31_20110731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_2_20130614_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-13</startDate>
      <endDate>2013-06-14</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_715329x739390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">insv:ScientificAdvisoryBoardStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_715329x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x843611">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">insv:NotePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_714750x1078421">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">insv:DebtExtinguishmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_711809x1077187">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:AzaSiteXtraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_711809x1077186">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:AzaSiteMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20130630_0_715329x739390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">insv:ScientificAdvisoryBoardStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20130630_0_715329x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20130630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20130630_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_181_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_1_20140610_0_714750x843611">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">insv:NotePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-10</startDate>
      <endDate>2014-06-10</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_1_20140610_0_711809x1077186">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:AzaSiteMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-10</startDate>
      <endDate>2014-06-10</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_1_20140610_0_711809x1077185">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:AkornIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-10</startDate>
      <endDate>2014-06-10</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_1_20140610_0_711502x716112_714750x843611">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">insv:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-10</startDate>
      <endDate>2014-06-10</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_1_20080229_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <startDate>2008-02-29</startDate>
      <endDate>2008-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20131231_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20140630_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20140630_0_708293x857455_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">insv:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20130531_0_711809x726294">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20130531_0_705999x716283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110430_0_711809x726294">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110430_0_705999x716283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20080229_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2008-02-29</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20140811_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
    </entity>
    <period>
      <instant>2014-08-11</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-07-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110731_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-07-31</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110526_0_711809x726294">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">insv:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-05-26</instant>
    </period>
  </context>
  <context id="eol_PE5378----1410-Q0004_STD_0_20110526_0_705999x716283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000802724</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-05-26</instant>
    </period>
  </context>
  <unit id="Patent">
    <measure>insv:Patent</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Warrants">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>insv:Warrants</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Segment">
    <measure>insv:Segment</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_10" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_13" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_14" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_15" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_15" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_16" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_17" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_18" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_18" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_19" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_19" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_2" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_20" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_20" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_21" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_21" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_22" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_23" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_23" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_24" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_24" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_26" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_27" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_27" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_28" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_28" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_29" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_29" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_3" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_30" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_30" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_31" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_31" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_32" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_32" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_33" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_33" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_34" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_34" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_35" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_35" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_36" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_36" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_37" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_37" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_38" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_38" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_39" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_39" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_4" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_5" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_6" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_7" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_8" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_9" xlink:label="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_9" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_281694921" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Derived from the Company's audited consolidated financial statements as of December 31, 2013.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_10" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_13" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_14" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_15" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_16" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_17" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_18" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_19" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_2" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_20" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_21" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_22" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_23" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_24" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_26" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_27" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_28" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_29" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_3" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_30" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_31" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_32" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_33" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_34" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_35" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_36" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_37" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_38" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_39" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_4" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_5" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_6" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_7" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_8" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3815551_C7EA0AED-3CA1-4E63-9006-5AC35A58226E_2_9" xlink:to="footnote_281694921" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>